Indoco Remedies shares jump as Goa plant passes UK MHRA cGMP inspection

Indoco Remedies Ltd., a leading Indian pharmaceutical firm, saw its shares climb after its manufacturing facility in Goa successfully cleared a current Good Manufacturing Practice (cGMP) inspection conducted by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA inspection, part of the agency’s effort to ensure that overseas sites meet UK standards for drug quality and safety, concluded that the Goa plant complies with the required cGMP guidelines. The clearance enables the company to continue supplying products to the UK market without interruption. Following the announcement, the stock rose on the BSE and NSE, reflecting investor confidence in the firm’s regulatory compliance and its ability to access export markets. Analysts noted that the positive outcome could bolster Indoco’s growth prospects, especially as it seeks to expand its presence in regulated markets.